Topgen Pharmaceuticals

About Topgen Pharmaceuticals

Established in September 2012, Topgen Pharmaceuticals, legally registered as Zhejiang Shaoxing Topgen Biopharmaceutical Technology Co., Ltd., is a high-tech enterprise focused on the integration, research, and sales of precision medicine technologies and products. The company was co-founded by CEO Shen Weiqiang and Vice General Manager Luo Peng, who oversees sales and marketing. Situated initially in Shanghai's Zhangjiang International Medical Park, the company leverages its strategic location to foster collaborations and innovation.

Topgen Pharmaceuticals operates on a dual-driver business model, combining third-party laboratory services (ICL) with the development of in-vitro diagnostic (IVD) products. Its core technological focus is on high-throughput sequencing, supplemented by capabilities in real-time fluorescent quantitative PCR and digital PCR. The company provides a comprehensive suite of precision medicine services primarily targeting oncology, including companion diagnostics, early screening, disease monitoring, and personalized medication guidance. Its client base extends to over 830 Grade-A tertiary hospitals across more than 23 provinces in China, in addition to research institutions and pharmaceutical companies. Revenue is generated through these laboratory services and the sale of diagnostic kits.

The company's product portfolio is extensive, with over 100 active products covering a wide range of cancers such as lung, colorectal, breast, and thyroid cancer. A notable achievement is the development of a novel NGS test kit for thyroid cancer. Topgen has established a nationwide network, including multiple medical laboratories and a GMP-certified production facility. The company has secured significant funding through several rounds, including an A round in June 2015, a B round in March 2017, a 120 million RMB C round in July 2020, and a D1 round of over 100 million RMB announced in late 2021 or early 2022. These funds are directed towards expanding its laboratory network and enhancing R&D and production capabilities.